Hope S Rugo1, Jeffrey Voigt2. 1. Department of Medicine (Hematology/Oncology), Director Breast Oncology Clinical Trials Program, University of California San Francisco, San Francisco, CA. 2. Medical Device Consultants of Ridgewood LLC, Ridgewood, NJ. Electronic address: jdv4957@aol.com.
Abstract
BACKGROUND: Alopecia is a side effect of chemotherapy and affects a patient's quality of life. Cooling the scalp during chemotherapy might reduce alopecia. The objective of this systematic and meta-analysis was to examine the effects of scalp cooling on the end point of alopecia in randomized controlled trials. MATERIALS AND METHODS: Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Electronic searches of databases were undertaken through February 2017. In addition other sources were searched. All languages were considered for evaluation. Data were collected and evaluated using a data collection form. Assessment of biases was undertaken using Cochrane methods. When studies could be combined, binary outcomes were evaluated using risk ratio assessment and continuous outcomes were assessed using mean difference (MD). Confidence intervals (CIs) were included and heterogeneity using the I2 statistic. Grading of Recommendations, Assessment, Development, and Evaluation assessments were also made. RESULTS: Ten studies were included in the analysis comprised of 654 patients. Most were patients with breast cancer 432 patients [66%] mainly receiving anthracyclines. For the binary outcome of < 50% versus > 50% alopecia, the use of scalp cooling reduced relative risk (RR) of alopecia by 43% (RR, 0.57; 95% CI, 0.45-0.72; I2 = 11%; P < .00001). For ordinal outcomes (alopecia on a scale of 0-3), use of scalp cooling significantly reduced alopecia (MD, -0.80; 95% CI, -1.19 to -0.41; I2 = 0%; P < .0001). The quality of the evidence was graded as moderate. CONCLUSION: This systematic review and meta-analysis supports the use of scalp cooling to prevent alopecia in patients with solid tumors undergoing chemotherapy.
BACKGROUND: Alopecia is a side effect of chemotherapy and affects a patient's quality of life. Cooling the scalp during chemotherapy might reduce alopecia. The objective of this systematic and meta-analysis was to examine the effects of scalp cooling on the end point of alopecia in randomized controlled trials. MATERIALS AND METHODS: Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Electronic searches of databases were undertaken through February 2017. In addition other sources were searched. All languages were considered for evaluation. Data were collected and evaluated using a data collection form. Assessment of biases was undertaken using Cochrane methods. When studies could be combined, binary outcomes were evaluated using risk ratio assessment and continuous outcomes were assessed using mean difference (MD). Confidence intervals (CIs) were included and heterogeneity using the I2 statistic. Grading of Recommendations, Assessment, Development, and Evaluation assessments were also made. RESULTS: Ten studies were included in the analysis comprised of 654 patients. Most were patients with breast cancer 432 patients [66%] mainly receiving anthracyclines. For the binary outcome of < 50% versus > 50% alopecia, the use of scalp cooling reduced relative risk (RR) of alopecia by 43% (RR, 0.57; 95% CI, 0.45-0.72; I2 = 11%; P < .00001). For ordinal outcomes (alopecia on a scale of 0-3), use of scalp cooling significantly reduced alopecia (MD, -0.80; 95% CI, -1.19 to -0.41; I2 = 0%; P < .0001). The quality of the evidence was graded as moderate. CONCLUSION: This systematic review and meta-analysis supports the use of scalp cooling to prevent alopecia in patients with solid tumors undergoing chemotherapy.
Authors: Cornelia Kolberg-Liedtke; Diana Lüftner; Sara Y Brucker; Wilfried Budach; Carsten Denkert; Peter A Fasching; Renate Haidinger; Nadia Harbeck; Jens Huober; Christian Jackisch; Wolfgang Janni; David Krug; Thorsten Kühn; Sibylle Loibl; Volkmar Müller; Andreas Schneeweiss; Christoph Thomssen; Michael Untch; Marc Thill Journal: Breast Care (Basel) Date: 2022-04-08 Impact factor: 2.268
Authors: Anne Versluis; Kirsten van Alphen; Wouter Dercksen; Henk de Haas; Corina van den Hurk; Ad A Kaptein Journal: Support Care Cancer Date: 2022-01-20 Impact factor: 3.603
Authors: Ludwike W M van Kalmthout; Marnix G E H Lam; Bart de Keizer; Gerard C Krijger; Tessa F T Ververs; Rememrt de Roos; Arthur J A T Braat Journal: EJNMMI Res Date: 2018-07-03 Impact factor: 3.138
Authors: Jade Cury-Martins; Adriana Pessoa Mendes Eris; Cristina Martinez Zugaib Abdalla; Giselle de Barros Silva; Veronica Paula Torel de Moura; Jose Antonio Sanches Journal: An Bras Dermatol Date: 2020-02-15 Impact factor: 1.896
Authors: Franz-Ferdinand Bitto; Alexander König; Thuy Phan-Brehm; Thomas Vallbracht; Julian Gregor Koch; Timo Schinköthe; Matthias Wolfgarten; Sven Mahner; Nadia Harbeck; Rachel Würstlein Journal: Breast Care (Basel) Date: 2019-07-25 Impact factor: 2.860